Relevance of in vitro SCREENIT results for drug-induced QT interval prolongation in vivo: A database review and analysis

Pharmacology and Therapeutics

Volumn 119, Issue 2, 2008, Pages 152-159

  Dumotier, B M ^a   Deurinck, M ^a   Yang, Y ^a   Traebert, M ^a   Suter, W ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

hERG assay; Isolated rabbit heart; Monophasic action potentials; QT interval prolongation; Torsade de pointes

Indexed keywords

POTASSIUM CHANNEL BLOCKING AGENT; POTASSIUM CHANNEL HERG;

ANIMAL TISSUE; ASSAY; BLOOD LEVEL; DOG; DRUG INDUCED DISEASE; ELECTROCARDIOGRAM; FALSE NEGATIVE RESULT; FALSE POSITIVE RESULT; HEART MUSCLE POTENTIAL; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MODEL; MONKEY; NONHUMAN; PREDICTION; PRIORITY JOURNAL; QT INTERVAL; QT PROLONGATION; RABBIT; REVIEW; TELEMETRY;

ANIMALS; DATABASES, FACTUAL; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; ETHER-A-GO-GO POTASSIUM CHANNELS; HEART; INHIBITORY CONCENTRATION 50; LONG QT SYNDROME; PHARMACEUTICAL PREPARATIONS; RABBITS; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; TELEMETRY;

EID: 50049133717     PISSN: 01637258     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pharmthera.2008.03.001     Document Type: Review

References (23)

1. Ando K., Hombo T., Kanno A., Ikeda H., Imaizumi M., Shimizu N., et al. QT PRODACT: in vivo QT assay with a conscious monkey for assessment of the potential for drug-induced QT interval prolongation. Journal of Pharmacology Science 99 (2005) 487-500
2. Antzelevitch C., Belardinelli L., Wu L., Fraser H., Zygmunt A.C., Burashnikov A., et al. Electrophysiologic properties and antiarrhythmic actions of a novel antianginal agent. Journal of Cardiovascular Pharmacology and Therapeutics 9 (2004) S65-S83
3. Carlsson L., Almgren O., and Duker G. QTU-prolongation and torsades de pointes induced by putative class III antiarrhythmic agents in the rabbit - Etiology and interventions. Journal of Cardiovascular Pharmacology 16 (1990) 276-285
4. Dennis A., Wang L., Wan X., and Ficker E. hERG channel trafficking: Novel targets in drug-induced long QT syndrome. Biochemical Society Transactions 35 (2007) 1060-1063
5. Dessertenne F. La tachycardie ventriculaire a deux foyers opposes variables. Archives des Maladies du Coeur 59 (1966) 263-272
6. Dumotier B.M., and Georgieva A.V. Preclinical cardio-safety assessment of torsadogenic risk and alternative methods to animal experimentation: The inseparable twins. Cell Biology and Toxicology 23 (2007) 293-302
7. Eckhardt L.L., Rajamani S., and January C.T. Protein trafficking abnormalities: A new mechanism in drug-induced long QT syndrome. British Journal of Pharmacology 145 (2005) 3-4
8. Fridericia L.S. Die Systolendauer im Elektrokardiogramm bei normalen Menschen und bei Herzkranken. Acta Medica Scandinavica 53 (1920) 469-486
9. Hondeghem L.M. Computer aided development of antiarrhythmic agents with class IIIa properties. Journal of Cardiovascular Electrophysiology 5 (1994) 711-721
10. Hondeghem L.M. Thorough QT/QTc not so thorough: removes torsadogenic predictors from the T-wave, incriminates safe drugs, and misses profibrillatory drugs. Journa of Cardiovascular Electrophysiology 17 (2006) 337-340
11. Hondeghem L.M., and Hoffmann P. Blinded test in the isolated female rabbit heart reliably identifies action potential duration prolongation and proarrhythmic drugs: Importance of triangulation, reverse use-dependence, and instability. Journal of Cardiovascular Pharmacology 41 (2003) 14-24
12. Hondeghem L.M., Lu H.R., van Rossem K., and De Clerck F. Detection of proarrhythmia in the female rabbit heart: Blinded validation. Journal of Cardiovascular Electrophysiology 14 (2003) 287-294
13. Iost N., Virág L., Opincariu M., Szécsi J., Varró A., and Papp J.G. Delayed rectifier potassium current in undiseased human ventricular myocytes. Cardiovascular Research 40 (1998) 508-515
14. Kuryshev Y.A., Ficker E., Wang L., Hawryluk P., Dennis A.T., Wible B.A., et al. Pentamidine-induced long QT syndrome and block of hERG trafficking. Journal of Pharmacology and Exprimental Therapeutics 312 (2005) 316-323
15. Lawrence C.L., Bridgland-Taylor M.H., Pollard C.E., Hammond T.G., and Valentin J.P. A rabbit Langendorff heart proarrhythmia model: Predictive value for clinical identification of Torsades de Pointes. British Journal of Pharmacology 149 (2006) 845-860
16. Mitcheson J.S., and Hancox J.C. An investigation of the role played by the E-4031-sensitive (rapid delayed rectifier) potassium current in isolated rabbit atrioventricular nodal and ventricular myocytes. Pflugers Archiv 438 (1999) 843-850
17. Miyazaki H., Watanabe H., Kitayama T., Nishida M., Nishi Y., Sekiya K., et al. QT PRODACT: Sensitivity and specificity of the canine telemetry assay for detecting drug-induced QT interval prolongation. Journal of Pharmacology Science 99 (2005) 523-529
18. Morganroth J. Comparative efficacy and safety of oral mexiletine and quinidine in benign or potentially lethal ventricular arrhythmias. American Journal of Cardiology 60 (1987) 1276-1281
19. Redfern W.S., Carlsson L., Davis A.S., Lynch W.G., MacKenzie I., Palethorpe S., et al. Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: Evidence for a provisional safety margin in drug development. Cardiovascular Research 58 (2003) 32-45
20. Shah R.R. Can pharmacogenetics help rescue drugs withdrawn from the market?. Pharmacogenomics 7 (2006) 889-908
21. Thomsen M.B., Verduyn S.C., Stengl M., Beekman J.D., de Pater G., van Opstal J., et al. Increased short-term variability of repolarization predicts d-sotalol-induced torsades de pointes in dogs. Circulation 110 (2004) 2453-2459
22. Van de Water A., Verheyen J., Xhonneux R., and Reneman R.S. An improved method to correct the QT interval of the electrocardiogram for changes in heart rate. Journal of Pharmacology Methods 22 (1989) 207-217
23. Vos M.A., Verduyn S.C., Gorgels A.P.M., Lipcsei G.C., and Wellens H.J.J. Reproducible induction of early after depolarizations and torsade de pointes arrhythmias by d-sotalol and pacing in dogs with chronic atrioventricular block. Circulation 91 (1995) 864-872